Insulin Analogue for Diabetes
Novo Nordisk has announced the FDA’s approval of Levemir®, a soluble, long-acting (basal) human insulin analogue for the treatment of diabetes. This agent has already been approved for use in 37 countries.
This analogue has a relatively flat action profile with a prolonged duration of action of up to 24 hours. It is indicated for once-daily or twice-daily subcutaneous administration for adults with diabetes mellitus who require basal insulin to control hyperglycemia.
The FDA is expected to decide on its use in children before the end of 2005.
